# **Guidelines for Abstract Submission**

#### GENERAL INFORMATION

- Abstracts must be written in clear English and submitted prior to November 30 (Sat.), 2024 at 11:59PM(KST).
- The abstract submission system will request the following information about the abstract you are submitting.
  - Main interest of the abstract
    - i. Ovarian Cancer
    - ii. Uterine Cancer
    - iii. Cervical Cancer
    - iv. Endometrial hyperplasia
    - v. Cervical intraepithelial neoplasia
    - vi. Others
  - ② Purpose of the abstract
    - i. Prevention
    - ii. Diagnosis
    - iii. Treatment
    - iv. Prognosis
    - v. Translational research
    - vi. Others
  - Type of the abstract (can be changed according to the Final decision)
    - i. Plenary
    - ii. Oral
    - iii. Poster
    - iv. Surgical film
    - v. Case report
    - vi. Trial in Progress
    - vii. Late breaking abstract
    - viii. Invited lecture
  - Case report and Trials in Progress should be submitted solely in Poster.
  - Late breaking abstract (LBA): The initial version of LBA, as called shell abstract should be submitted during the regular submission period. The 'final version of LBA' should then be resubmitted during the 2024 January submission period for LBA and Trial in Progress. LBA will be reviewed in its final version and researchers will be informed of the results.
  - Domestic members can submit Original Research, Case report, Late-breaking Abstract and Trials in Progress.
  - Those from overseas and other departments such as the Korean Society of Pathologists and Korean Society for Radiation Oncology can submit Original Research, Case report, Late-breaking Abstract, and Trials in Progress.
  - To promote submissions by overseas researchers, overseas researchers can submit their submissions in January as well.

- Authors may further edit and modify submitted abstracts until the submission deadline
- Research work to be presented should be original and not already published as a full paper.
- The content of the abstract may have been presented at another prior meeting, but you are encouraged to add new information/data.
- It is the responsibility of the authors to ensure that their text does not contain typos or grammatical errors.
- Authors have the option of choosing their presentation types, but the scientific program committee will make the final decision after review.
- The right to publish your abstract is granted to the KSGO 2025 Organizing Committee.
- Abstracts stating "data will be discussed in the presentation" will NOT be accepted.

## PREPARING YOUR ABSTRACTS

- Abstracts should be no more than 250 words (350 words for Trials in Progress) including spaces for the total of abstract body, not including abstract title, author names, and affiliation.
- Please, ensure that all the information of byline including names and affiliations of all the authors in the uploaded MS Word file is correct.
- All authors should not include the name of the institution in the title and method.
- General instruction: font 10 size (Times New Roman), double space between lines.
- Photographs (radiographs, CT/MRI scans, and scanned images) must have a resolution of at least 300 dpi. and either one table or figure is allowed.
- Video file sizes do not exceed up to 350MB (MPG or WMV), and video files should be submitted by using a URL/URI/External Resource.
- Sections of your abstracts are as follows
  - > Original research: Objective, Methods, Results, and Conclusions
  - > Case report (Poster only) or surgical film: unstructured
  - > Trial in Progress (<u>Poster only</u>): Background, and Methods (Trial registration ID and resources should be shown)
- Late-breaking abstracts include only phase 2 or 3 trials, large-scale cohort or big-data studies, and encore abstracts selected in major meetings, including 2024 SGO, ASCO, and AACR.

### **PUBLICATION OF ABSTRACTS**

- For your information, the Journal of Gynecologic Oncology (JGO), the official journal of KSGO, will publish the selected abstracts of KSGO 2025 as a supplement issue.
- The JGO supplement is an open access issue and searchable. Please be aware that you may not be able
  to submit the JGO published abstracts of KSGO 2025 to some of the international conferences that do not
  accept encore abstracts.

## **ABSTRACT EMBARGO POLICY**

- Abstract titles, authors, and affiliations may be made public upon acceptance by the Scientific Committee.
- All abstracts are available on the meeting website. Regular abstracts will be published 7 days prior to the
  meeting, and late-breaking abstracts will be published on the first day of the meeting on the meeting
  homepage.

## **INQUIRY**

- Secretariat of KSGO 2025
- Tel. +82 2 512 5915, 0044 | Email. office@sqo.or.kr